A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation

Type: Article

Publication Date: 2014-05-12

Citations: 30

DOI: https://doi.org/10.1002/sim.6200

Abstract

Interim monitoring is routinely conducted in phase II clinical trials to terminate the trial early if the experimental treatment is futile. Interim monitoring requires that patients' responses be ascertained shortly after the initiation of treatment so that the outcomes are known by the time the interim decision must be made. However, in some cases, response outcomes require a long time to be assessed, which causes difficulties for interim monitoring. To address this issue, we propose a Bayesian trial design to allow for continuously monitoring phase II clinical trials in the presence of delayed responses. We treat the delayed responses as missing data and handle them using a multiple imputation approach. Extensive simulations show that the proposed design yields desirable operating characteristics under various settings and dramatically reduces the trial duration. Copyright © 2014 John Wiley & Sons, Ltd.

Locations

  • PubMed Central - View
  • Europe PMC (PubMed Central) - View - PDF
  • PubMed - View
  • Statistics in Medicine - View

Similar Works

Action Title Year Authors
+ PDF Chat Bayesian sequential monitoring design for two‐arm randomized clinical trials with noncompliance 2015 Weining Shen
Jing Ning
Ying Yuan
+ PDF Chat A Bayesian dose‐finding design for phase I/II clinical trials with nonignorable dropouts 2015 Beibei Guo
Ying Yuan
+ PDF Chat A two‐stage group‐sequential design for delayed treatment responses with the possibility of trial restart 2024 Stephen Schüürhuis
Frank Konietschke
Cornelia Ursula Kunz
+ A Bayesian–frequentist two‐stage single‐arm phase II clinical trial design 2012 Gaohong Dong
Weichung Joe Shih
Dirk F. Moore
Hui Quan
Stephen Marcella
+ Bayesian Interim Inference of Probability of Clinical Trial Success 2013 Ming‐Dauh Wang
Grace Ying Li
+ A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology 2019 Shinjo Yada
+ PDF Chat A Simulation Study to Decide the Timing of an Interim Analysis in a Bayesian Adaptive Dose-Finding Studies with Delayed Responses 2016 Xiaobi Huang
+ A randomized Bayesian optimal phase II design with binary endpoint 2022 Yang Ding
+ Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes 2018 Ming Zhou
Qi Tang
Lixin Lang
Jun Xing
Kay Tatsuoka
+ Bayesian Multi-Stage Designs for Phase II Clinical Trials 2019 Harry Yang
Steven Novick
+ Bayesian enhancement two‐stage design with error control for phase II clinical trials 2020 Huaqing Jin
Guosheng Yin
+ Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility 2017 Stephen D. Walter
Hye Ree Han
Matthias Briel
Gordon Guyatt
+ PDF Chat A Bayesian phase I/II clinical trial design in the presence of informative dropouts 2015 Beibei Guo
Yong Zang
Ying Yuan
+ Bayesian Enhancement Two-Stage Design for Single-Arm Phase II Clinical Trials with Binary and Time-to-Event Endpoints 2018 Haolun Shi
Guosheng Yin
+ BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints 2017 Heng Zhou
J. Jack Lee
Ying Yuan
+ A Bayesian sequential design using alpha spending function to control type I error 2015 Han Zhu
Qingzhao Yu
+ Bayesian Optimal Adaptive Designs for Delayed-Response Dose-Finding Studies 2011 Wen Li
Haoda Fu
+ Bayesian Optimal Phase II Design for Randomized Clinical Trials 2022 Yujie Zhao
Bo Yang
J. Jack Lee
Li Wang
Ying Yuan
+ Bayesian Optimal Phase II Design for Randomized Clinical Trials 2022 Yujie Zhao
Bo Yang
J. Jack Lee
Li Wang
Ying Yuan
+ Interim treatment selection with a flexible selection margin in clinical trials 2012 Yujun Wu
Peng‐Liang Zhao

Works That Cite This (28)

Action Title Year Authors
+ A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints 2024 Xiaohan Chi
Ying Yuan
Zhangsheng Yu
Ruitao Lin
+ PDF Chat A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison 2024 Yong Zang
Peter F. Thall
Ying Yuan
+ An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints 2019 Beibei Guo
Suyu Liu
+ A Bayesian hierarchical monitoring design for phase <scp>II</scp> cancer clinical trials: Incorporating information on response duration into monitoring rules 2021 Jian Wang
Junsheng Ma
Chunyan Cai
Naval Daver
Jing Ning
+ Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update 2019 Rebecca S.S. Tidwell
S. Andrew Peng
Minxing Chen
Diane D. Liu
Ying Yuan
J. Jack Lee
+ Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer–A Perspective on Future Trial Designs 2019 Steffen Ventz
Lorenzo Trippa
Jonathan D. Schoenfeld
+ PDF Chat Adaptive designs for drug combination informed by longitudinal model for the response 2019 Tobias Mielke
Vladimir Dragalin
+ PDF Chat When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay 2022 Aritra Mukherjee
James Wason
Michael J. Grayling
+ PDF Chat Thompson Sampling with Unrestricted Delays 2022 Han Wu
Stefan Wager
+ PDF Chat Phase II two-stage single-arm clinical trials for testing toxicity levels 2019 Seong Ho Kim
Weng Kee Wong